BPC-157 Gets Its First Controlled Human Trial: Inside the Hamstring-Strain Study

What Is the New BPC-157 Human Trial, and Why Does It Matter?

ClinicalTrials.gov registration NCT07437547, titled “BPC 157 for Acute Hamstring Muscle Strain Repair,” is a randomised, double-blind, placebo-controlled Phase 2 study of pentadecapeptide BPC-157, sponsored by Hudson Biotech.[1] It is significant for a simple reason: despite years of preclinical interest and heavy consumer demand for BPC-157 as a research and self-experimentation compound, no properly controlled human trial had ever reached an active recruiting stage until this one began in February 2026.[2]

BPC-157, covered in our BPC-157 research overview, is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein BPC. Preclinical rodent literature has associated it with angiogenic and tissue-repair signalling, but that body of work has never been matched by controlled human data — a gap that has been the central criticism of BPC-157's evidence base in independent reporting.[3] Velox Peptides supplies BPC-157 as an HPLC-verified reagent for in vitro research use only. View the product page →

How Is the Hamstring-Strain Trial Designed?

The trial enrols adults aged 18 to 45 presenting with posterior thigh pain consistent with a hamstring strain, with symptom onset within 72 hours of screening and injury severity confirmed by MRI as grade II.[1] Participants are randomised to receive BPC-157 or placebo for 14 days, alongside a standardised rehabilitation programme applied identically to both arms so that any treatment effect can be isolated from the rehab protocol itself.

The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14 — one functional outcome and one objective imaging outcome, reported together rather than in isolation.[1] Estimated primary completion is February 2027, with topline results expected in the first half of 2027.[2]

Has BPC-157 Ever Been Tested in Humans Before?

One earlier registration exists on ClinicalTrials.gov: NCT02637284, filed in December 2015 by PharmaCotherapia to assess the safety and pharmacokinetics of an oral BPC-157 formulation designated PCO-02.[4] A decade later, that record still carries an unknown recruitment status, and no results have ever been posted. For practical purposes, it never produced usable human data.

A February 2026 STAT News investigation into BPC-157 summarised the resulting evidence gap bluntly: strong consumer and clinician interest, an established rodent literature, but scant controlled human evidence to support any specific claim about the compound's effects in people.[3] The Hudson Biotech trial is the first attempt to close that gap with data generated under blinded, controlled conditions rather than anecdote.

How Does This Connect to the FDA's Compounding Review of BPC-157?

The trial's timing is not incidental. In July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to vote on whether BPC-157, alongside TB-500, MOTS-c and four other peptides, should be added to the 503A Category 1 Bulks List, which would formally permit licensed US compounding pharmacies to prepare it. The committee narrowly recommended BPC-157 by an 8-6 vote (one abstention), but FDA career scientists reviewing the docket stated openly that the available studies — including five trials of BPC-157 — were short in duration, small in sample size, and insufficient to establish safety or effectiveness for the indications under review.[5] Our PCAC July 2026 guide covers that hearing and vote in full.

NCT07437547 is the first study specifically designed to produce the kind of controlled human data PCAC reviewers said was missing. It will not resolve the broader compounding debate on its own — it tests one indication, one dosing regimen, and one 14-day course — but it represents the first real attempt to generate primary evidence rather than rely on the preclinical and observational data that dominated the July 2026 hearing.

What Would the Results Mean for Research?

What Are the Limitations of This Trial Record?

Several caveats matter for anyone tracking this registration. First, it is a trial in progress: as of this article's publication no interim or topline data has been released, and the estimated primary completion date of February 2027 is a sponsor projection, not a guarantee.[1] Second, the trial tests a single narrow indication — acute grade II hamstring strain — and its results, whatever they show, cannot be generalised to other tissue types, injury grades, or the many other applications discussed in BPC-157's preclinical rodent literature. Third, the dosing formulation, purity standard, and regulatory pathway used in a sponsor-run clinical trial are not equivalent to any research-use peptide sold commercially, including Velox Peptides' own BPC-157 product.

None of this constitutes evidence of any safety, efficacy, or health outcome in humans, and nothing here describes a property of Velox Peptides' research-grade BPC-157, which is supplied strictly for in vitro laboratory use and carries no therapeutic or health-benefit claims.

Velox Peptides Supply Information

BPC-157 is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions